You just read:

BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor

News provided by

BioTheryX, Inc.

Jan 16, 2020, 09:00 ET